Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

Blood (2023) 141 (9): 1023–1035.

https://doi.org/10.1182/blood.2021015246

Published: 2023

Includes: Supplemental data

Journal Articles

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Maryam Ghalandary, Yuqiao Gao, Diana Amend, Ginte Kutkaite, Binje Vick, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinovic, Ehsan Bahrami, Irmela Jeremias

Blood (2023) 141 (8): 955–960.

https://doi.org/10.1182/blood.2022016411

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Daniel Bergér, Steffen Dickopf, Binje Vick, Katharina Weinlich, Irmela Jeremias, Ulrich Brinkmann, Christoph Klein

Blood (2022) 140 (Supplement 1): 2249–2250.

https://doi.org/10.1182/blood-2022-163104

Published: 2022

Journal Articles

Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

Sebastian E. Koschade, Kevin Klann, Shabnam Shaid, Binje Vick, Jan A. Stratmann, Marlyn Thölken, Laura M. Meyer, The Duy Nguyen, Julia Campe, Laura M. Moser, Susanna Hock, Fatima Baker, Christian Meyer, Frank Wempe, Hubert Serve, Evelyn Ullrich, Irmela Jeremias, Christian Münch, Christian H. Brandts

Blood (2022) 140 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2022-168824

Published: 2022

Journal Articles

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood (2022) 140 (10): 1104–1118.

https://doi.org/10.1182/blood.2022015956

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Blood (2021) 138 (25): 2655–2669.

https://doi.org/10.1182/blood.2020010477

Published: 2021

Includes: Supplemental data

Journal Articles

In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia

Ehsan Bahrami, Jan Philipp Schmid, Martin Becker, Anna-Katharina Wirth, Rupert Öllinger, Roland Rad, Binje Vick, Ashok Kumar Jayavelu, Matthias Mann, Tobias Herold, Irmela Jeremias

Blood (2021) 138 (Supplement 1): 708.

https://doi.org/10.1182/blood-2021-149658

Published: 2021

Journal Articles

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Dana Stenger, Tanja A. Stief, Theresa Kaeuferle, Semjon Willier, Felicitas Rataj, Kilian Schober, Binje Vick, Ramin Lotfi, Beate Wagner, Thomas G. P. Grünewald, Sebastian Kobold, Dirk H. Busch, Irmela Jeremias, Franziska Blaeschke, Tobias Feuchtinger

Blood (2020) 136 (12): 1407–1418.

https://doi.org/10.1182/blood.2020005185

Published: 2020

Includes: Supplemental data

Journal Articles

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Siret Tahk, Saskia Schmitt, Christian Peter Augsberger, Binje Vick, PhD, Laia Pascual Ponce, PhD, Irmela Jeremias, MD PhD, Georg Wittmann, MD, Nadja Fenn, PhD, Marion Subklewe, MD, Karl-Peter Hopfner, PhD

Blood (2019) 134 (Supplement_1): 2544.

https://doi.org/10.1182/blood-2019-128145

Published: 2019

Journal Articles

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Christina Maria Zeller, MSc, Daniel Richter, MSc, Binje Vick, PhD, Tobias Herold, MD, Johannes Bagnoli, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Wolfgang Enard, PhD, Irmela Jeremias, MD PhD

Blood (2019) 134 (Supplement_1): 1450.

https://doi.org/10.1182/blood-2019-127867

Published: 2019

Journal Articles

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Blood (2019) 134 (3): 263–276.

https://doi.org/10.1182/blood.2018862383

Published: 2019

Includes: Supplemental data

Journal Articles

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

Sophie M. Stief, M.Sc., Anna-Li Hanneforth, Raphael Mattes, Sabrina Weser, M.Sc., Binje Vick, PhD, Michael D. Bartoschek, M.Sc., Helena Domínguez Moreno, M.Sc., Wen-Hsin Liu, PhD, Bianka Ksienzyk, Maja Rothenberg-Thurley, PhD, Hilmar Quentmeier, PhD, Wolfgang Hiddemann, Klaus H. Metzeler, MD, Gunnar Schotta, PhD, Sebastian Bultmann, PhD, Irmela Jeremias, MD PhD, Heinrich Leonhardt, PhD, Karsten Spiekermann, MD

Blood (2018) 132 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2018-99-114959

Published: 2018

Journal Articles

Long-Term Dormant Cells in Acute Myeloid Leukemia Patient-Derived Xenografts Display Reversible Treatment Resistance, but Are Not Enriched for Leukemia-Initiating Cells

Sarah Ebinger, MSc, Binje Vick, PhD, Karsten Spiekermann, MD, Irmela Jeremias, MD PhD

Blood (2018) 132 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2018-99-109731

Published: 2018

Journal Articles

Therapy‐Induced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia

Martin Schönlein, J. Henry M. Däbritz, Dorothy Ngo-Yin Fan, Jana Ihlow, Rolf Schwarzer, Binje Vick, Karsten Spiekermann, Thomas Burmeister, Jörg Westermann, Irmela Jeremias, Clemens A. Schmitt

Blood (2017) 130 (Supplement 1): 1393.

https://doi.org/10.1182/blood.V130.Suppl_1.1393.1393

Published: 2017

Journal Articles

Peptide-Receptor Radiotherapy with CXCR4-Targeting Pentixather Reduces Leukemia Burden in Acute Leukemia PDX and Patients

Stefan Habringer, MD, Peter Herhaus, Margret Schottelius, PhD, Constantin Lapa, MD, Rouzanna Istvanffy, PhD, Katharina Götze, Katja Steiger, DVM, Binje Vick, PhD, Christian Peschel, MD, Robert Oostendorp, PhD, Irmela Jeremias, MD, Hans-Jürgen Wester, PhD, Goetz Ulrich Grigoleit, MD, Ulrich Keller, MD

Blood (2016) 128 (22): 4055.

https://doi.org/10.1182/blood.V128.22.4055.4055

Published: 2016

Journal Articles

Targeting the ER-Mitochondrial Interface of Cell Death Sensitizes Leukemia Cells Towards Cytostatics

Fabian Koczian, Jan Vomacka, Binje Vick, PhD, Britta F Hettich, Uli Kazmaier, Stephan A Sieber, Irmela Jeremias, MD, Angelika M Vollmar, Simone Braig

Blood (2016) 128 (22): 2319.

https://doi.org/10.1182/blood.V128.22.2319.2319

Published: 2016

Journal Articles

Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

Katrin S. Reiter, Harald Polzer, PhD, Christina Krupka, Binje Vick, PhD, Andreas Maiser, Marion S. Subklewe, MD, Irmela Jeremias, MD, Heinrich Leonhardt, PhD, Karsten Spiekermann, MD, Philipp A. Greif, MD

Blood (2015) 126 (23): 1274.

https://doi.org/10.1182/blood.V126.23.1274.1274

Published: 2015

Journal Articles

Azacitidine in Combination with the Selective FLT3 Kinase Inhibitor Crenolanib Effectively Disrupts Stromal Protection of CD34+ Leukemia-Initiating Cells (LIC) in FLT3-ITD+ Acute Myeloid Leukemia (AML)

Anne-Kathrin Garz, M.Sc., Stefan Habringer, Saskia Wolf, Binje Vick, PhD, Marie-Theresa Weickert, M.Sc., Irmela Jeremias, MD, Karsten Spiekermann, MD, Christian Peschel, MD, Robert A.J. Oostendorp, PhD, Ulrich Keller, Katharina S. Götze, MD

Blood (2015) 126 (23): 676.

https://doi.org/10.1182/blood.V126.23.676.676

Published: 2015

Journal Articles

Bioluminescence in Vivo Imaging Improves the Model of Individual Patients' AML Cells Growing in Mice for Sensitive and Reliable Preclinical Treatment Trials on Various Genetic Subgroups

Irmela Jeremias, MD, Binje Vick, Dr., Maya Rothenberg, Nadine Sandhöfer, MSc, Michela Carlet, PhD, Christina Krupka, Andreas Trumpp, PhD, Selim Corbacioglu, MD, Martin Ebinger, MD, Maya Caroline Andre, MD, Wolfgang Hiddemann, MD, Stephanie Schneider, PhD, Marion Subklewe, MD, Klaus H Metzeler, MD, Karsten Spiekermann, MD

Blood (2014) 124 (21): 2323.

https://doi.org/10.1182/blood.V124.21.2323.2323

Published: 2014

NARROW

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

Long-Term Dormant Cells in Acute Myeloid Leukemia Patient-Derived Xenografts Display Reversible Treatment Resistance, but Are Not Enriched for Leukemia-Initiating Cells

Therapy‐Induced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia

Peptide-Receptor Radiotherapy with CXCR4-Targeting Pentixather Reduces Leukemia Burden in Acute Leukemia PDX and Patients

Targeting the ER-Mitochondrial Interface of Cell Death Sensitizes Leukemia Cells Towards Cytostatics

Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

Azacitidine in Combination with the Selective FLT3 Kinase Inhibitor Crenolanib Effectively Disrupts Stromal Protection of CD34+ Leukemia-Initiating Cells (LIC) in FLT3-ITD+ Acute Myeloid Leukemia (AML)

Bioluminescence in Vivo Imaging Improves the Model of Individual Patients' AML Cells Growing in Mice for Sensitive and Reliable Preclinical Treatment Trials on Various Genetic Subgroups

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only